Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Regulated
Regulated Information Ghent, BELGIUM – 3 February 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces in accordance with article 14 of the Belgian Act of 2 May 2007 on the disclosure of...
Read More
Regulated Information Ghent, Belgium, 29 January 2020 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations...
Read More
Regulated information   Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfapump® in the U.S. & Canada Achieved clinical proof-of-concept of Direct Sodium Removal (DSR), potential breakthrough therapy for volume overload due to heart failure Conference call with live webcast presentation today at 14:00 CET /...
Read More
Experienced MedTech Executive Jason Hannon appointed as Non-Executive Director Ghent, BELGIUM – 23 May 2019 (18:00 CEST) – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today...
Read More
Regulated Information Ghent, BELGIUM – 23 April 2019 (18:00 CEST) – Sequana Medical NV (“Sequana Medical” or the “Company“) (Euronext Brussels: SEQUA), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces that its Annual...
Read More
Ghent, BELGIUM – 4 April 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical device company focused on innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces its business highlights and financial results for the year ended 31 December 2018, prepared...
Read More
Regulated Information Ghent, BELGIUM – 26 March 2019 (19:00 CET) – Sequana Medical NV [Euronext Brussels: SEQUA] (“Sequana Medical”, the “Company”) today invited the holders of securities issued by the Company to attend an extraordinary shareholders’ meeting before notary public on Thursday 25 April 2019. The agenda items of the extraordinary shareholders’ meeting relate to...
Read More
Ghent, BELGIUM – 18 March 2019 (5.30 PM CET) – Today, Sequana Medical NV (“Sequana Medical” or the “Company“), announces the end of the stabilisation period in the framework of the initial public offering of new shares of the Company with the admission of all of its shares to trading on the regulated market of...
Read More
Ghent, BELGIUM – 1 March 2019 – Within the framework of the initial public offering of new shares of Sequana Medical NV (“Sequana Medical” or the “Company“), with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol “SEQUA” (the “Offering“), KBC Securities NV/SA has been...
Read More
Ghent, BELGIUM – 25 February 2019 – Sequana Medical NV (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today in accordance with article 14 of the Belgian Act of...
Read More
1 6 7 8 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES